Literature DB >> 3080423

Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures.

D C Stump, H R Lijnen, D Collen.   

Abstract

A urokinase-type plasminogen activator was purified from conditioned media of several human cell cultures, but preferably from the human lung adenocarcinoma line CALU-3 (ATCC, HTB-55), using a combination of chromatography on zinc chelate-Sepharose, SP-Sephadex C-50, and Sephadex G-100. Final yields of 65-100 micrograms/liter of starting material were obtained with a 290-fold purification factor and a recovery of 30%. The purified plasminogen activator consists of a single polypeptide chain with Mr 54,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and is very similar or identical to single-chain urokinase-type plasminogen activator on the basis of immunodiffusion, amino acid composition, and the lack of specific binding to fibrin. It has very low amidolytic activity on Pyroglu-Gly-Arg-rho-nitroanilide and is converted to two-chain urokinase by limited exposure to plasmin. It has a specific activity of 60,000 IU/mg on fibrin plates and directly activates plasminogen following Michaelis-Menten kinetics with Km = 1.1 microM and kappa cat = 0.0026 S-1. It is concluded that the plasminogen activator purified from CALU-3-conditioned media is physically and kinetically identical to single-chain urokinase-type plasminogen activator. With the present straightforward purification method and a readily available source, sufficient amounts of single-chain urokinase-type plasminogen activator can be obtained for more detailed investigations of its biochemical, biological, and thrombolytic properties.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080423

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Novel thrombolytic agents.

Authors:  M Verstraete; H R Lijnen
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

2.  A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.

Authors:  J N Liu; V Gurewich
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

3.  Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.

Authors:  Erica Atkins; Stephanie Zamora; Britny J Candia; Amy Baca; Robert A Orlando
Journal:  Cytotechnology       Date:  2005-09       Impact factor: 2.058

4.  Urokinase separation from cell culture broth of a human kidney cell line.

Authors:  Vibha Bansal; Pradip K Roychoudhury; Ashok Kumar
Journal:  Int J Biol Sci       Date:  2006-11-22       Impact factor: 6.580

Review 5.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors.

Authors:  F Blasi; J D Vassalli; K Danø
Journal:  J Cell Biol       Date:  1987-04       Impact factor: 10.539

6.  Inactivation of human tumor cell pro-urokinase by granulocyte elastase.

Authors:  N Kanayama; T Terao
Journal:  Jpn J Cancer Res       Date:  1990-10

7.  Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis.

Authors:  J M Heiple; L Ossowski
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

8.  Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in the progression of human breast cancer.

Authors:  J I Yamashita; M Ogawa; S Ikei; H Omachi; S I Yamashita; T Saishoji; K Nomura; H Sato
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.